Opioids Flashcards
Which of the following is true, according to SAMSHA in regards to medications for opioid use disorder (OUD)?
Check all that apply.
a. The science demonstrating the effectiveness of medication for OUD is strong
b. Addiction is a chronic, treatable disease
c. FDA-approved medication should be considered and offered to pts with OUD as part of their treatment
d. There is no “one size fits all” approach to OUD treatment
b. Addiction is a chronic, treatable disease
c. FDA-approved medication should be considered and offered to pts with OUD as part of their treatment
d. There is no “one size fits all” approach to OUD treatment
Suboxone is the brand name for a combination of buprenorphine and naloxone.
a. True
b. False
a. True
Naloxone is added to burpenorphine in a drug used to manage OUD so that the potential to abuse the drug is reduced when naloxone is released during crushing, melting, or latering the tablets.
a. True
b. False
a. True
Which of the following is NOT a treatment strategy to engage patietns in shared-decision-making about OUD treatment?
a. Offer only 1 treatment option at a time to pts
b. Explore the patient’s existing knowledge base
c. Express your desire to collaborate with them
d. Include family members in the treatment planning process, if possible
a. Offer only 1 treatment option at a time to pts
According to SAMSHA, extended-release nalotrexone (XR_NTX) should be considered for patients who:
a. Have responded to prior treatment with opioid agonists
b. Prefer to take opioid agonists like buprenorphine or methadone
c. Have used opioids in the last week
Consider naltrexone for pts:
* Who do not wish to take opioid agonists
* Who have been opioid abstinent for at least a week (perhaps those who are being released from controlled environments
* Who do not have access to opioids agonist tx (think rural)
* Who have not responded well to prior adequate tx with opioid agonist regimens
